| Completed | Increasing Men's Engagement in Preventive Healthcare Through an Enhanced Cocoon Vaccination Strategy NCT06437834 | Case Western Reserve University | N/A |
| Not Yet Recruiting | A Multifaceted Intervention on Reducing Immunization Errors NCT06745635 | Hospital Israelita Albert Einstein | N/A |
| Completed | The Next Generation Vaccine Card: Innovative Technology to Improve Vaccine Equity in Rural and Urban Settings NCT06470919 | University of Michigan | N/A |
| Completed | A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Ag NCT06179446 | Pfizer | Phase 1 |
| Active Not Recruiting | Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Voluntee NCT05993325 | Cellid Co., Ltd. | Phase 3 |
| Unknown | Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Pro NCT06259487 | Wroclaw Medical University | N/A |
| Completed | Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products NCT02242968 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Medicine-induced Cardiac Hemodialysis on COVID-19 NCT05711810 | Yang I. Pachankis | Phase 4 |
| Completed | Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 NCT05593042 | Pontificia Universidad Catolica de Chile | Phase 2 |
| Completed | Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake NCT05586178 | University of California, Los Angeles | N/A |
| Completed | Effects of Prompt to Bundle COVID-19 Booster and Flu Shot NCT05586165 | University of California, Los Angeles | N/A |
| Completed | Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up NCT05586204 | University of California, Los Angeles | N/A |
| Completed | Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Sa NCT05284097 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine NCT05576623 | Cellid Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 NCT05520970 | Cellid Co., Ltd. | Phase 2 |
| Unknown | Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chi NCT05494047 | Pontificia Universidad Catolica de Chile | Phase 3 |
| Active Not Recruiting | Korea Comirnaty Post-marketing Surveillance NCT05032976 | Pfizer | — |
| Unknown | Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVac NCT05084950 | Centre Scientifique de Monaco | — |
| Completed | Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years NCT05470582 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Unknown | Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. NCT04388033 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 / Phase 2 |
| Completed | Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 i NCT04651790 | Pontificia Universidad Catolica de Chile | Phase 3 |
| Completed | Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine NCT05457894 | St. Petersburg Research Institute of Vaccines and Sera | Phase 3 |
| Completed | Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae T NCT05401305 | St. Petersburg Research Institute of Vaccines and Sera | Phase 1 |
| Completed | Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In I NCT03777865 | Pfizer | Phase 4 |
| Completed | Patient Portal - Flu Reminder Recall NCT03666026 | University of California, Los Angeles | N/A |
| Unknown | Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine NCT03776994 | SRI International | Phase 1 |
| Completed | Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Fo NCT03548337 | Pfizer | Phase 4 |
| Completed | Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2 NCT03392207 | Butantan Institute | — |
| Completed | HPV Centralized R/R RCT #2 - New York State NCT03294551 | University of California, Los Angeles | N/A |
| Completed | Centralized Reminder Recall - Flu RCT2 NCT03294473 | University of California, Los Angeles | N/A |
| Completed | Immunization Services Model for Adult Rate Improvement NCT02609035 | Pharmacy Quality Alliance | N/A |
| Completed | Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patie NCT02692976 | Radboud University Medical Center | Phase 2 |
| Completed | A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With o NCT01697007 | Muhimbili University of Health and Allied Sciences | Phase 2 |
| Completed | A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adu NCT01672645 | Pfizer | Phase 1 |
| Completed | A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vacc NCT01461993 | Pfizer | Phase 2 |
| Completed | A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Va NCT01461980 | Pfizer | Phase 2 |
| Completed | The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Mont NCT01306006 | Bandim Health Project | Phase 4 |
| Completed | Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan NCT00688870 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | Experimental Vaccine for Plasmodium Falciparum Malaria NCT00340431 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |